Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16180381 | 1.00 | TK1 (0.43) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL657377 | 1.00 | TK1 (0.43) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL15895622 | 1.00 | TK1 (0.43) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL15893331 | 1.00 | TK1 (0.43) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL11780860 | 1.00 | TK1 (0.43) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL24254562 | 1.00 | TK1 (0.43) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL15893328 | 1.00 | TK1 (0.43) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL16180380 | 1.00 | TK1 (0.43) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL9153935 | 0.91 | TK1 (0.38) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL9443827 | 0.88 | TK1 (0.36) | TK1LMNASMN1; SMN2ADRB1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-20160082133-A1 | CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MRI USING REPORTER GENES AND SUBSTRATES AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | claimed |
| WO-2014172359-A1 | CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MRI USING REPORTER GENES AND SUBSTRATES AND METHODS THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-23 | — | — | WO | claimed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230295694-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-09-21 | — | — | US | disclosed |
| EP-1419247-A2 | METHOD FOR THE PRODUCTION OF NUCLEIC ACIDS CONSISTING OF STOCHASTICALLY COMBINED PARTS OF SOURCE NUCLEIC ACIDS | Direvo Biotech AG (DE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003012100-A2 | METHOD FOR THE PRODUCTION OF NUCLEIC ACIDS CONSISTING OF STOCHASTICALLY COMBINED PARTS OF SOURCE NUCLEIC ACIDS | DIREVO BIOTECH AG (DE) | 2003-02-13 | — | — | WO | disclosed |
| EP-1281757-A1 | Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids | Direvo Biotech AG (DE) | 2003-02-05 | — | — | EP | disclosed |
| EP-0626970-A1 | DIHYDROPYRIMIDINE NUCLEOSIDES WITH ANTIVIRAL PROPERTIES | THE UNIVERSITY OF ALBERTA (CA) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994014831-A1 | DIHYDROPYRIMIDINE NUCLEOSIDES WITH ANTIVIRAL PROPERTIES | THE UNIVERSITY OF ALBERTA (CA) | 1994-07-07 | — | — | WO | disclosed |
| US-5204456-A | Derivatives of nucleosides and their use for the synthesis of oligonucleotides | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1993-04-20 | — | — | US | disclosed |
| US-5179200-A | N4-(3-PHENYLPROPRIONYL)-2'-DEOXYCYTIDINE | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1993-01-12 | — | — | US | disclosed |
| US-4980460-A | Protected nucleosides which permit more efficient oligonucleotide syntheses | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1990-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | TK1 1713/4885LMNA 3119/4885SMN1; SMN2 3068/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | TK1 565/4885LMNA 3363/4885SMN1; SMN2 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.